Falkenried 88, Haus A
20251 Hamburg GERMANY
+49 40 302089010
info@topas-therapeutics.com
Meet with Topas at the following industry events this fall:
Hamburg, 27th September 2018 – Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural tolerance induction capabilities of the liver, today announced that the Company will participate at the following conferences this fall:
Topas will host 1X1 meetings at this event. To request a meeting with Topas, please sign up through the event’s partneringONE meeting system. The 24 th annual global life science partnering event is expected to bring together over 4,000 executives from 2,200+ life science companies spanning an estimated 60+ countries to engage in one-to-one partnering. For more information, please click here.
Meetings around JP Morgan 36th Annual Global Healthcare Conference
January 8–11, 2019
San Francisco, CA, USA
During the week of the JP Morgan Global Healthcare Conference in San Francisco, Topas will meet with investors, potential partners and other interested parties. Please contact Timm Jessen (jessen@topas-therapeutics.com) if you are interested in meeting that week.
Immunology of Diabetes Society Congress 2018
October 25–29, 2018
London, United Kingdom
The Company will attend this scientific conference. The conference is for researchers with an interest in the immunology of diabetes and autoimmunity as well as those interested in gaining a greater understanding of the disease and the development of new therapeutic strategies. For more information, click here.
Antigen-Specific Immune Tolerance Europe Conference
December 10–12, 2018
London, United Kingdom
Timm Jessen will give a talk entitled, “Liver Based Immune Tolerance Induction,” on December 12th at 9:30 AM GMT.
Tackling key R&D; challenges, such as antigen identification, animal model predictability, translation and clinical design, this conference is the first European centric, dedicated platform that brings key decision makers together to successfully translate ground breaking science into a novel class of therapies to treat autoimmunity. Please click here for more details about the event.
About Topas Therapeutics
Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s natural immunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering. Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction, and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies. Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund. For additional information, please visit: www.topas-therapeutics.com.
Topas Therapeutics GmbH
Dr. Timm-H. Jessen
CEO / Managing Director
Falkenried 88
20251 Hamburg
Email: jessen@topas-therapeutics.com
Web: www.topas-therapeutics.com
Media Relations Europe
MC Services AG
Anne Hennecke
Phone: +49 211 529252-22
Email: anne.hennecke@mc-services.eu
Media Relations U.S.
Laurie Doyle
Phone: +1 339 8320752
Email: laurie.doyle@mc-services.eu
Web: www.mc-services.eu